Pharmaceutical News

5 Strategies to Make New Drugs Surpass Their Predecessors Five strategies to outperform first-in-class (FIC) drugs and achieve best-in-class (BIC) status. From identifying new indications and enhancing selectivity to optimizing pharmacokinetics and developing dual-function molecules.
FDA approves AbbVie's 24-hour subcutaneous infusion therapy AbbVie FDA The FDA has approved AbbVie’s VYALEV (ABBV-951), a 24-hour continuous subcutaneous infusion therapy for advanced Parkinson's disease. This first-of-its-kind treatment, based on levodopa, offers significant improvements in motor fluctuations and prolongs "on" time with fewer complications.
A Leading Asian Pharmaceutical Company Launches GLP-1 Microneedle Daewoong Pharma Daewoong Therapeutics, a subsidiary of Daewoong Pharmaceutical, has launched CLOPAM®, an innovative GLP-1 microneedle platform designed to treat diabetes and obesity. This dissolvable microneedle patch offers pain-free drug delivery, reducing hospital visits and enhancing patient adherence.
Johnson & Johnson: Cuts 5 Pipelines, Including Neurology and Oncology Johnson & Johnson Johnson & Johnson's Q3 2024 report reveals major pipeline cuts, including mid-stage neurology and oncology programs. Despite positive results in Alzheimer's and depression treatments, the company halted key projects in Parkinson’s, bipolar disorder, and mantle cell lymphoma.
Pfizer's RSV Vaccine Shows 90% Efficacy Against Severe Respiratory Diseases Pfizer Pfizer's RSV vaccine, Abrysvo, shows 90% efficacy against severe respiratory illness in older adults, highlighting its potential as RSV cases rise. Despite CDC's narrower vaccination guidelines, Abrysvo remains a key product, nearing $1 billion in sales within seven months of FDA approval.
Many Seek Beauty: 380 Million Investment, Long-Lasting Botulinum Toxin Approved Botulinum toxin China has approved DAXXIFY® (RT002), a long-lasting botulinum toxin formulation by Sisram Medical Technology, for temporarily improving glabellar lines. Using patented Peptide Exchange Technology, this marks a significant advancement in neuromodulation.
Top 10 Key Readouts in Q4 2024 Drug Development Top 10 key clinical readouts in drug development for Q4 2024, spanning treatments for obesity, depression, Alzheimer's, pain, muscular atrophy, schizophrenia, and more. These updates involve a variety of drug modalities including monoclonal antibodies, CAR-T, proteins, and peptides.
FDA Approves Roche's PI3Kα Inhibitor - Doubled PFS! FDA Roche The FDA approved Genentech's PI3Kα inhibitor, Inavolisib (Itovebi), in combination with palbociclib and fulvestrant for advanced breast cancer patients with PIK3CA mutations. The therapy showed a significant 57% reduction in disease progression in the Phase III INAVO120 trial.
Eli Lilly Leadership Changes Eli Lilly Eli Lilly announces major leadership changes, appointing Thomas J. Fuchs as its first Chief AI Officer, highlighting the company's commitment to AI-driven healthcare innovation. Additionally, Yan Qiong joins as VP of the Diabetes Business Unit, boosting growth in China's market.
Big Pharma to Shape the Future of Cell and Gene Therapy Catapult Matthew Durdy, CEO of Cell and Gene Therapy Catapult, led a panel at the 2024 MESA Conference alongside pharma leaders from Pfizer, Bayer, BMS, and Eli Lilly. They discussed Big Pharma's growing role in the cell and gene therapy sector, addressing commercialization challenges.